Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1551
{ "count": 24593, "next": "http://api.gregory-ms.com/articles/?format=api&page=1552", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1550", "results": [ { "article_id": 381629, "title": "Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial", "summary": "<jats:sec><jats:title>Objective:</jats:title><jats:p> Our aim was to assess the usefulness of cranberry extract in multiple sclerosis (MS) patients suffering from urinary disorders. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> In total, 171 adult MS outpatients with urinary disorders presenting at eight centers were randomized (stratification according to center and use of clean intermittent self-catheterization) to cranberry versus placebo in a 1-year, prospective, double-blind study that was analyzed using a sequential method on an intent-to-treat basis. An independent monitoring board analyzed the results of the analyses each time 40 patients were assessed on the main endpoint. Cranberry extract (36 mg proanthocyanidins per day) or a matching placebo was taken by participants twice daily for 1 year. The primary endpoint was the time to first symptomatic urinary tract infection (UTI), subject to validation by a validation committee. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The second sequential analyses allowed us to accept the null hypothesis (no difference between cranberry and placebo). There was no difference in time to first symptomatic UTI distribution across 1 year, with an estimated hazard ratio of 0.99, 95% CI [0.61, 1.60] ( p = 0.97). Secondary endpoints and tolerance did not differ between groups. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Taking cranberry extract versus placebo twice a day did not prevent UTI occurrence in MS patients with urinary disorders. Trial Registration NCT00280592. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458514549402", "published_date": "2014-01-08T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 250338, "given_name": "Cécile", "family_name": "Donzé", "ORCID": null, "country": null }, { "author_id": 312301, "given_name": "Jacques", "family_name": "Kerdraon", "ORCID": null, "country": null }, { "author_id": 293975, "given_name": "Marianne", "family_name": "de Seze", "ORCID": null, "country": null }, { "author_id": 270575, "given_name": "Pierre", "family_name": "Denys", "ORCID": null, "country": null }, { "author_id": 312302, "given_name": "Alain", "family_name": "Renault", "ORCID": null, "country": null }, { "author_id": 312303, "given_name": "Florian", "family_name": "Naudet", "ORCID": null, "country": null }, { "author_id": 312304, "given_name": "Jean Michel", "family_name": "Reymann", "ORCID": null, "country": null }, { "author_id": 250340, "given_name": "Philippe", "family_name": "Gallien", "ORCID": null, "country": null }, { "author_id": 268602, "given_name": "Gérard", "family_name": "Amarenco", "ORCID": null, "country": null }, { "author_id": 312299, "given_name": "Nicolas", "family_name": "Benoit", "ORCID": null, "country": null }, { "author_id": 312300, "given_name": "Véronique", "family_name": "Bonniaud", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Cranberry", "placebo", "the prevention", "urinary infections", "multiple sclerosis", "a multicenter", "placebo-controlled, double-blind trial" ], "doi": "10.1177/1352458513517592", "access": "restricted", "takeaways": " Cranberry extract (36 mg proanthocyanidins per day) or a matching placebo was taken by participants twice daily for 1 year . The primary endpoint was the time to first symptomatic urinary tract infection (UTI)", "categories": [] }, { "article_id": 381246, "title": "Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue", "summary": "<jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate the dynamic temporal changes of brain resting-state functional connectivity (RS-FC) following mental effort in multiple sclerosis (MS) patients with cognitive fatigue (CF). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Twenty-two MS patients, 11 with (F) and 11 without CF, and 12 healthy controls were included. Separate RS-FC scans were acquired on a 3T MR scanner immediately before ( t0), immediately after ( t1) and 30 minutes after ( t2) execution of the paced auditory serial addition test (PASAT), a cognitively demanding task. Subjectively perceived CF after PASAT execution was also assessed. RS-FC changes were investigated by using a data-driven approach (the Intrinsic Connectivity Contrast<jats:sub>-power</jats:sub>), complemented by a priori defined regions of interest analyses. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The F-group patients experienced stronger RS-FC at t2 between the left superior frontal gyrus (L-SFG) and occipital, frontal and temporal areas, which increased over time after PASAT execution. In the F-group patients, the L-SFG was hyperconnected at t1 with the left caudate nucleus and hypoconnected at t2 with the left anterior thalamus. These variations were correlated with both subjectively perceived and clinically assessed CF, and—for the left thalamus—with PASAT performance. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> The development of cortico–cortical and cortico–subcortical hyperconnectivity following mental effort is related to CF symptoms in MS patients. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458515625806", "published_date": "2016-07-11T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 163703, "given_name": "Emanuele", "family_name": "Pravatà", "ORCID": "http://orcid.org/0000-0002-5225-2993", "country": null }, { "author_id": 151309, "given_name": "Chiara", "family_name": "Zecca", "ORCID": "http://orcid.org/0000-0002-9990-3431", "country": "CH" }, { "author_id": 270350, "given_name": "Carlo", "family_name": "Sestieri", "ORCID": null, "country": null }, { "author_id": 295677, "given_name": "Massimo", "family_name": "Caulo", "ORCID": null, "country": null }, { "author_id": 262386, "given_name": "Gianna Carla", "family_name": "Riccitelli", "ORCID": null, "country": null }, { "author_id": 241616, "given_name": "Maria Assunta", "family_name": "Rocca", "ORCID": null, "country": null }, { "author_id": 143061, "given_name": "Massimo", "family_name": "Filippi", "ORCID": "http://orcid.org/0000-0002-5485-0479", "country": null }, { "author_id": 270352, "given_name": "Alessandro", "family_name": "Cianfoni", "ORCID": null, "country": null }, { "author_id": 151308, "given_name": "Claudio", "family_name": "Gobbi", "ORCID": "http://orcid.org/0000-0002-7554-0664", "country": "CH" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Hyperconnectivity", "the dorsolateral prefrontal cortex", "mental effort", "multiple sclerosis patients", "cognitive fatigue" ], "doi": "10.1177/1352458515625806", "access": "restricted", "takeaways": " Twenty-two MS patients, 11 with (F) and 11 without CF, and 12 healthy controls were included . Separate RS-FC scans were acquired on a 3T MR scanner immediately before ( t0), immediately after ( t1) and 30 minutes after (t2) execution of the paced auditory serial addition test (PASAT)", "categories": [] }, { "article_id": 381798, "title": "Demographic and clinical factors associated with changes in employment in multiple sclerosis", "summary": "<jats:sec><jats:title>Objective:</jats:title><jats:p> The objective of this paper is to investigate demographic and disease factors associated with changes in employment role and status in multiple sclerosis (MS). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Questionnaires on current symptoms, employment status and factors associated with changes in employment were sent to a community sample of 566 MS patients. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 221 completed questionnaires were analysed. Of 169 employed at diagnosis, 43.3% had left employment at a mean of 11.9 years after disease onset. Of those still employed, 55% had changed their role or working hours to accommodate symptoms relating to their disease. These patients reported greater fatigue ( p = 0.001), pain ( p = 0.033) and memory problems ( p = 0.038) than those whose employment had remained unaffected. Multinomial logistic regression revealed the factors most strongly predictive of employment status were disability level, years of education, disease duration and fatigue ( p = 0.032). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Despite changes to public perceptions and legislative protection over the last 20 years, high rates of MS patients still leave the workforce prematurely, reduce working hours or change employment roles. These data have significant implications when considering social and economic impacts of MS, support the value of employment metrics as long-term outcome measures, and demonstrate the need to improve employment requirements and flexibility of working practices in individuals with MS. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-05-07T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 307139, "given_name": "Phil", "family_name": "Moore", "ORCID": null, "country": null }, { "author_id": 273777, "given_name": "Katharine E", "family_name": "Harding", "ORCID": null, "country": null }, { "author_id": 307140, "given_name": "Hannah", "family_name": "Clarkson", "ORCID": null, "country": null }, { "author_id": 256906, "given_name": "Trevor P", "family_name": "Pickersgill", "ORCID": null, "country": null }, { "author_id": 256905, "given_name": "Mark", "family_name": "Wardle", "ORCID": null, "country": null }, { "author_id": 230375, "given_name": "Neil P", "family_name": "Robertson", "ORCID": "http://orcid.org/0000-0002-5409-4909", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Demographic and clinical factors", "changes", "employment", "multiple sclerosis" ], "doi": "10.1177/1352458513481396", "access": "restricted", "takeaways": " Questionnaires on symptoms, employment status and factors associated with changes in employment were sent to a community sample of 566 MS patients . Of those still employed, 55% had changed their role or working hours to accommodate symptoms relating to their disease . Factors most strongly predictive of employment status were disability level, years of education, disease duration and fatigue .", "categories": [] }, { "article_id": 381192, "title": "Indirect comparisons of treatment effects: Network meta-analyses", "summary": "<jats:p> Many therapeutic options are now available for patients with multiple sclerosis. While the efficacy of each drug has been assessed against placebo or, more recently, against interferon, no direct comparisons of these new therapies have been conducted in randomized clinical trials. Therefore, indirect treatment comparisons are needed to inform clinical decisions. In this brief report, some basic concepts about network meta-analyses that are the formal methods used to run multiple indirect treatment comparisons are reviewed when applied in the context of multiple sclerosis studies. </jats:p>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517690272", "published_date": "2017-02-17T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 149329, "given_name": "Maria Pia", "family_name": "Sormani", "ORCID": "http://orcid.org/0000-0001-6892-104X", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Indirect comparisons", "treatment effects", "Network meta-analyses" ], "doi": "10.1177/1352458517690272", "access": "restricted", "takeaways": " Many therapeutic options are now available for patients with multiple sclerosis . No direct comparisons of these new therapies have been conducted in randomized clinical trials . Therefore, indirect treatment comparisons are needed to inform clinical decisions .", "categories": [] }, { "article_id": 380892, "title": "Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Debate exists about whether neuromyelitis optica spectrum disorder seronegative disease represents the same immune-mediated attack on astrocytic aquaporin-4 as in seropositive disease. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> We investigated whether response to common treatments for neuromyelitis optica spectrum disorder differed by serostatus, as assessed by change in annualized relapse rate. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We performed a multicenter retrospective analysis of 245 patients with neuromyelitis optica spectrum disorder who were treated with either rituximab or mycophenolate mofetil as their first-line immunosuppressive treatment for disease prevention. Patients were followed for a minimum of 6 months following treatment initiation. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In those started on rituximab, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.81 and 1.93, respectively. On-treatment annualized relapse rates significantly declined to 0.32 (seropositive; p < 0.0001) and 0.12 (seronegative; p = 0.0001). In those started on mycophenolate mofetil, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.79 and 1.45, respectively. On-treatment annualized relapse rates declined to 0.29 (seropositive; p < 0.0001) and 0.30 (seronegative; p < 0.005). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> In this international collaboration involving a large number of neuromyelitis optica spectrum disorder patients, treatment was effective regardless of serostatus. This suggests that treatment should not differ when considering these treatments. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517730131", "published_date": "2017-08-31T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 224430, "given_name": "Maureen A", "family_name": "Mealy", "ORCID": "http://orcid.org/0000-0001-8967-6338", "country": null }, { "author_id": 148906, "given_name": "Su-Hyun", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-0679-0918", "country": null }, { "author_id": 290868, "given_name": "Felix", "family_name": "Schmidt", "ORCID": null, "country": null }, { "author_id": 290869, "given_name": "Reydmar", "family_name": "López", "ORCID": null, "country": null }, { "author_id": 290870, "given_name": "Jorge A", "family_name": "Jimenez Arango", "ORCID": null, "country": null }, { "author_id": 237109, "given_name": "Friedemann", "family_name": "Paul", "ORCID": "https://orcid.org/0000-0002-6378-0070", "country": "DE" }, { "author_id": 245538, "given_name": "Dean M", "family_name": "Wingerchuk", "ORCID": null, "country": null }, { "author_id": 152354, "given_name": "Benjamin M", "family_name": "Greenberg", "ORCID": "http://orcid.org/0000-0002-2091-8201", "country": null }, { "author_id": 148923, "given_name": "Ho Jin", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-8672-8419", "country": null }, { "author_id": 143704, "given_name": "Michael", "family_name": "Levy", "ORCID": "http://orcid.org/0000-0002-7969-8346", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Aquaporin-4 serostatus", "response", "immunotherapy", "neuromyelitis optica spectrum disorders" ], "doi": "10.1177/1352458517730131", "access": "open", "takeaways": " Debate exists about whether neuromyelitis optica spectrum disorder seronegative disease represents the same immune-mediated attack on astrocytic aquaporin-4 as in seropositive disease . We investigated whether response to common treatments differed by serostatus as assessed by change in annualized relapse rate .", "categories": [] }, { "article_id": 381815, "title": "Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis – a systematic review", "summary": "<jats:p> Despite many epidemiological studies examining comorbidity in people with multiple sclerosis (pMS), there are conflicting opinions on whether pMS are at more or less risk of cardiovascular disease (CVD) and the metabolic syndrome compared with the general population. As pMS can now expect longer survival, this as an important question both at an individual and public health level. This study aimed to systematically review the literature linking MS to CVD risks and to the risk factors constituting the metabolic syndrome. This systematic review is based on a comprehensive literature search of six databases (Swemed+, Pubmed, Embase, Cochrane, PEDro and CINAHL). In total 34 studies were identified. Despite the high number of identified papers, only limited and inconsistent data exist on the risk factors of the metabolic syndrome and MS. Overall, the data suggest an increased CVD risk in pMS. From the existing studies it is not clear whether the increased risk of CVD is related to an increased risk of obesity or changes in body composition, hypertension, dyslipidemia or type II diabetes in pMS, indicating the need for future research in the field, if we are to advise pMS adequately in avoiding preventable comorbidity. </jats:p>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-09-18T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 265205, "given_name": "Inez", "family_name": "Wens", "ORCID": null, "country": null }, { "author_id": 146787, "given_name": "Ulrik", "family_name": "Dalgas", "ORCID": "http://orcid.org/0000-0003-4132-2789", "country": null }, { "author_id": 194950, "given_name": "Egon", "family_name": "Stenager", "ORCID": "http://orcid.org/0000-0002-4877-5193", "country": null }, { "author_id": 265206, "given_name": "Bert O", "family_name": "Eijnde", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Risk factors", "cardiovascular diseases", "the metabolic syndrome", "multiple sclerosis", "a systematic review" ], "doi": "10.1177/1352458513504252", "access": "restricted", "takeaways": " There are conflicting opinions on whether pMS are at more or less risk of cardiovascular disease (CVD) and the metabolic syndrome compared with the general population . As pMS can now expect longer survival, this as an important question both at an individual and public health level .", "categories": [] }, { "article_id": 380905, "title": "On-road assessment of fitness-to-drive in persons with MS with cognitive impairment: A prospective study", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Cognitive impairment is common in multiple sclerosis (MS). In other populations, cognitive impairment is known to affect fitness-to-drive. Few studies have focused on fitness-to-drive in MS and no studies have solely focused on the influence of cognitive impairment. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To assess fitness-to-drive in persons with MS with cognitive impairment and low physical disability. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Persons with MS, aged 18–59 years with EDSS ⩽ 4.0, impaired processing speed, and impairment on at least one measure of memory or executive function, were recruited. Cognition was assessed using the Minimal Assessment of Cognitive Function battery. A formal on-road driving assessment was conducted. Chi-square analysis examined the association between the fitness-to-drive (pass/fail) and the neuropsychological test results (normal/impaired). Bayesian statistics predicting failure of the on-road assessment were calculated. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Of 36 subjects, eight (22.2%) were unfit to drive. Only the BVMTR-IR, measuring visual-spatial memory, predicted on-road driving assessment failure ( X<jats:sup>2</jats:sup> ( df = 1, N = 36) = 3.956; p = 0.047) with a sensitivity of 100%, but low specificity (35.7%) due to false positives (18/25). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> In persons with MS and impaired processing speed, impairment on the BVMTR-IR should lead clinicians to address fitness-to-drive. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517723991", "published_date": "2017-08-07T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 251383, "given_name": "Sarah A", "family_name": "Morrow", "ORCID": null, "country": null }, { "author_id": 243544, "given_name": "Sherrilene", "family_name": "Classen", "ORCID": null, "country": null }, { "author_id": 251391, "given_name": "Miriam", "family_name": "Monahan", "ORCID": null, "country": null }, { "author_id": 309416, "given_name": "Tim", "family_name": "Danter", "ORCID": null, "country": null }, { "author_id": 309417, "given_name": "Robert", "family_name": "Taylor", "ORCID": null, "country": null }, { "author_id": 243542, "given_name": "Sarah", "family_name": "Krasniuk", "ORCID": null, "country": null }, { "author_id": 247698, "given_name": "Heather", "family_name": "Rosehart", "ORCID": null, "country": null }, { "author_id": 251386, "given_name": "Wenqing", "family_name": "He", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "road", "persons", "MS", "cognitive impairment", "A prospective study" ], "doi": "10.1177/1352458517723991", "access": "restricted", "takeaways": " Cognitive impairment is common in multiple sclerosis (MS) In other populations, cognitive impairment is known to affect fitness-to-drive . Of 36 subjects, eight were unfit to drive . Only the BVMTR-IR, measuring visual-spatial memory, predicted on-road driving assessment failure .", "categories": [] }, { "article_id": 381074, "title": "miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> MicroRNAs (miRNAs) are non-coding RNAs that regulate cellular processes by controlling protein translation and mRNA degradation. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> We aimed to explore the miRNA signature of multiple sclerosis (MS) patients versus controls and the possibility that patients with lipid-specific oligolconal IgM bands (LS_OCMB), a predictor of a more severe disease course, may have a distinct profile. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> An extensive profile of 754 miRNAs was evaluated in the cerebrospinal fluid (CSF) of 14 women using TaqMan low-density arrays. Differentially expressed miRNAs together with others previously identified in the literature were validated in an extended sample of 86 MS patients (39 LS_OCMB+) and 55 controls. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We detected higher levels of miR-150 in MS patients and especially in those with LS_OCMB+. Other miRNAs (miR-328, miR-30a-5p and miR-645) were up-regulated in MS patients compared to controls while miR-21, miR-199a-3p, miR-191, miR-365, miR-106a and miR-146a showed down-regulated expression. Considering only patients with LS_OCMB+, we also detected up-regulation of miR-30a-5p, miR-150 and miR-645 and down-regulation of miR-191 compared to controls. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Our study confirms the recent findings regarding the deregulated expression of miR-150 not only with MS but also with the presence of LS_OCMB. This study highlights the potential utility of miRNAs in CSF as biomarkers for MS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458516684213", "published_date": "2017-01-09T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 175609, "given_name": "Ester", "family_name": "Quintana", "ORCID": "http://orcid.org/0000-0001-8885-1931", "country": null }, { "author_id": 311546, "given_name": "Francisco José", "family_name": "Ortega", "ORCID": null, "country": null }, { "author_id": 289561, "given_name": "René", "family_name": "Robles-Cedeño", "ORCID": null, "country": null }, { "author_id": 311547, "given_name": "María Luisa", "family_name": "Villar", "ORCID": null, "country": null }, { "author_id": 274541, "given_name": "Maria", "family_name": "Buxó", "ORCID": null, "country": null }, { "author_id": 311548, "given_name": "Josep Maria", "family_name": "Mercader", "ORCID": null, "country": null }, { "author_id": 311549, "given_name": "José Carlos", "family_name": "Alvarez-Cermeño", "ORCID": null, "country": null }, { "author_id": 311550, "given_name": "Neus", "family_name": "Pueyo", "ORCID": null, "country": null }, { "author_id": 311551, "given_name": "Héctor", "family_name": "Perkal", "ORCID": null, "country": null }, { "author_id": 275067, "given_name": "José Manuel", "family_name": "Fernández-Real", "ORCID": null, "country": null }, { "author_id": 205062, "given_name": "Lluís", "family_name": "Ramió-Torrentà", "ORCID": "http://orcid.org/0000-0002-6999-1004", "country": "ES" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "miRNAs", "cerebrospinal fluid", "patients", "MS", "specifically those", "lipid-specific oligoclonal IgM bands" ], "doi": "10.1177/1352458516684213", "access": "restricted", "takeaways": " MicroRNAs (miRNAs) are non-coding RNAs that regulate cellular processes by controlling protein translation and mRNA degradation . We found higher levels of miR-150 in MS patients and especially in those with LS_OCMB+.", "categories": [] }, { "article_id": 380701, "title": "Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Multiple sclerosis (MS) predominantly affects women of child-bearing potential. Pregnancy in MS is still a controversial issue lacking standardized treatment recommendations. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To examine the reciprocal effects of pregnancy, MS, and disease-modifying treatment (DMT). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We analyzed 387 pregnancies in 239 women with relapsing remitting multiple sclerosis (RRMS) and ⩾1 pregnancy, establishment of diagnosis >1 year before conception, and ⩾2 years of follow-up after delivery. Relapse rates and Expanded Disability Status Scale (EDSS) scores were compared in the year before conception, during pregnancy, and 2 years postpartum. Binary logistic regression was used to investigate predictors of risk for relapses and disability progression during pregnancy and postpartum. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Risk of relapse and disability progression during pregnancy was predicted by pre-conception relapse activity, higher EDSS score at conception, use of highly effective disease-modifying treatment (H-DMT) pre-conception, and prolonged washout period. Postpartum relapse and disability progression was associated with relapse activity pre-conception and during pregnancy and use of H-DMT pre-conception. Early restart of DMT reduced the risk of postpartum relapse. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> A personalized approach in planning pregnancy in women with MS while on H-DMT needs to be adopted. It seems reasonable maintaining natalizumab closer to conception and restarting the drug early postpartum to reduce the considerable risk of disease reactivation during early pregnancy and after delivery. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518816614", "published_date": "2018-12-03T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 147832, "given_name": "Gabriel", "family_name": "Bsteh", "ORCID": "http://orcid.org/0000-0002-0825-0851", "country": null }, { "author_id": 308509, "given_name": "Laura", "family_name": "Algrang", "ORCID": null, "country": null }, { "author_id": 147833, "given_name": "Harald", "family_name": "Hegen", "ORCID": "http://orcid.org/0000-0002-2833-6337", "country": null }, { "author_id": 152577, "given_name": "Michael", "family_name": "Auer", "ORCID": "http://orcid.org/0000-0002-5117-4225", "country": null }, { "author_id": 179630, "given_name": "Sebastian", "family_name": "Wurth", "ORCID": "http://orcid.org/0000-0001-7122-0842", "country": null }, { "author_id": 153251, "given_name": "Franziska", "family_name": "Di Pauli", "ORCID": "http://orcid.org/0000-0001-6183-2394", "country": null }, { "author_id": 147844, "given_name": "Florian", "family_name": "Deisenhammer", "ORCID": "http://orcid.org/0000-0003-4541-8841", "country": null }, { "author_id": 163862, "given_name": "Thomas", "family_name": "Berger", "ORCID": "http://orcid.org/0000-0001-5626-1144", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Pregnancy", "multiple sclerosis", "the DMT era", "A cohort study", "Western Austria" ], "doi": "10.1177/1352458518816614", "access": "open", "takeaways": " Pregnancy in MS is still a controversial issue lacking standardized treatment recommendations . We analyzed 387 pregnancies in 239 women with relapsing remitting multiple sclerosis (RRMS) and ⩾1 pregnancy . Risk of relapse and disability progression during pregnancy was predicted by pre-conception relapse activity, higher EDSS score at conception, use of highly effective disease-modifying treatment (H-DMT), and prolonged washout period .", "categories": [] }, { "article_id": 380536, "title": "Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif<jats:sup>®</jats:sup> Efficacy in Multiple Sclerosis) studies and their extensions. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519888610", "published_date": "2019-11-25T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 149342, "given_name": "Giancarlo", "family_name": "Comi", "ORCID": "http://orcid.org/0000-0002-6989-1054", "country": null }, { "author_id": 157717, "given_name": "Raed", "family_name": "Alroughani", "ORCID": "http://orcid.org/0000-0001-5436-5804", "country": null }, { "author_id": 309295, "given_name": "Aaron L", "family_name": "Boster", "ORCID": null, "country": null }, { "author_id": 258935, "given_name": "Ann D", "family_name": "Bass", "ORCID": null, "country": null }, { "author_id": 191860, "given_name": "Regina", "family_name": "Berkovich", "ORCID": "http://orcid.org/0000-0001-7637-0241", "country": null }, { "author_id": 148768, "given_name": "Óscar", "family_name": "Fernández", "ORCID": "http://orcid.org/0000-0003-3696-789X", "country": "ES" }, { "author_id": 148923, "given_name": "Ho Jin", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-8672-8419", "country": null }, { "author_id": 158671, "given_name": "Volker", "family_name": "Limmroth", "ORCID": "http://orcid.org/0000-0003-1607-2116", "country": null }, { "author_id": 173692, "given_name": "Jan", "family_name": "Lycke", "ORCID": "http://orcid.org/0000-0002-7891-8466", "country": null }, { "author_id": 309296, "given_name": "Richard AL", "family_name": "Macdonell", "ORCID": null, "country": null }, { "author_id": 143347, "given_name": "Basil", "family_name": "Sharrack", "ORCID": "http://orcid.org/0000-0003-2406-6365", "country": null }, { "author_id": 179201, "given_name": "Barry A", "family_name": "Singer", "ORCID": "http://orcid.org/0000-0001-6875-7374", "country": null }, { "author_id": 166338, "given_name": "Patrick", "family_name": "Vermersch", "ORCID": "http://orcid.org/0000-0003-0997-8817", "country": null }, { "author_id": 160394, "given_name": "Heinz", "family_name": "Wiendl", "ORCID": "http://orcid.org/0000-0003-4310-3432", "country": null }, { "author_id": 153754, "given_name": "Tjalf", "family_name": "Ziemssen", "ORCID": "http://orcid.org/0000-0001-8799-8202", "country": null }, { "author_id": 257008, "given_name": "Alan", "family_name": "Jacobs", "ORCID": null, "country": null }, { "author_id": 257011, "given_name": "Nadia", "family_name": "Daizadeh", "ORCID": null, "country": null }, { "author_id": 273248, "given_name": "Claudio E", "family_name": "Rodriguez", "ORCID": null, "country": null }, { "author_id": 219575, "given_name": "Anthony", "family_name": "Traboulsee", "ORCID": "http://orcid.org/0000-0002-0351-9639", "country": "CA" }, { "author_id": 260619, "given_name": "Darren P.", "family_name": "Baker", "ORCID": null, "country": null }, { "author_id": 309297, "given_name": "Ericka M.", "family_name": "Bueno", "ORCID": null, "country": null }, { "author_id": 309298, "given_name": "Colin", "family_name": "Mitchell", "ORCID": null, "country": null }, { "author_id": 309299, "given_name": "Rebecca L.", "family_name": "Orndorff", "ORCID": null, "country": null }, { "author_id": 309300, "given_name": "Valerie P.", "family_name": "Zediak", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Efficacy", "alemtuzumab", "relapsing-remitting MS patients", "who", "additional courses", "the initial two courses", "analysis", "the CARE-MS, extension", "TOPAZ studies" ], "doi": "10.1177/1352458519888610", "access": "open", "takeaways": " Alemtuzumab is given as two annual courses . Patients with continued disease activity may receive as-needed additional courses . In the additional-courses groups, Courses 3 and 4 reduced relapse rate .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 117 } ] } ] }